Jessica Reese
Women's Health · Henderson, TNNPI 1164872917
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 110 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 29 manufacturers reported payments, led by AbbVie at 27.9% of the total. Reporting peaked in 2023 at $493 and has fallen 56.6% since, to $214 in 2025.
Across 110 payments — averaging $16.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$499
- Novo Nordisk$193
- Takeda Pharmaceuticals U.S.A., Inc.$116
- Biogen$109
- Bayer$93
- Amgen$85
- plus $695 from 23 others
What the payments were for
- Food & beverage$1,790100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 40 | $499 |
| Novo Nordisk | 10 | $193 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $116 |
| Biogen | 4 | $109 |
| Bayer | 4 | $93 |
| Amgen | 6 | $85 |
| Exeltis, USA Inc. | 4 | $62 |
| Pfizer | 3 | $60 |
| AstraZeneca | 3 | $59 |
| Hologic Sales And Service, LLC | 2 | $50 |
| Lilly USA, LLC | 3 | $47 |
| Novartis | 3 | $41 |
| Mayne Pharma Commercial LLC | 3 | $39 |
| GSK | 2 | $36 |
| Biohaven Pharmaceuticals, Inc. | 2 | $34 |
| Lundbeck LLC | 2 | $30 |
| Coopersurgical, Inc. | 1 | $25 |
| Astellas Pharma US Inc | 1 | $21 |
| Pacira Pharmaceuticals Incorporated | 1 | $20 |
| Axsome Therapeutics, Inc. | 1 | $20 |
| Xeris Pharmaceuticals, Inc. | 1 | $19 |
| Sumitomo Pharma America, Inc. | 1 | $19 |
| Exact Sciences | 1 | $19 |
| Urovant Sciences Inc | 1 | $18 |
| Harmony Biosciences LLC | 1 | $18 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $15 |
| Otsuka America Pharmaceutical, Inc. | 1 | $15 |
| Avion Pharmaceuticals | 1 | $15 |
| Daiichi Sankyo Inc. | 1 | $14 |
How this compares
$1,790 in reported general payments places this provider in the 75th percentile of 202 women's health providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Rosuvastatin Calcium | 11 | $115 |
| Fluconazole | 19 | $84 |
Paid to pharmacies, not to this prescriber.
Other women's health in Henderson
- Haley WoodFranklin$92K
- Dana DemossNashville$76K
- Royanne MooreNashville$29K
- Laurie TompkinsBrentwood$27K
- Lana HirschNashville$24K
- Yoshie DarnallNashville$10K
- Lisa GoehringNashville$9K
- Anya ZerillaKnoxville$8K
- Catherine KingeryKnoxville$7K
- Lindsey BakshNashville$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.